human
metapneumoviru
hmpv
import
human
pathogen
along
respiratori
syncyti
viru
rsv
major
caus
respiratori
tract
infect
young
infant
develop
effect
vaccin
pneumovirus
proven
particularli
difficult
despit
year
research
field
vaccin
hmpv
rsv
current
avail
recombin
chimer
virus
express
antigen
virus
gener
revers
genet
use
simultan
immun
one
pathogen
approach
result
develop
promis
vaccin
candid
hmpv
sever
studi
inde
valid
viral
vector
express
hmpv
antigen
review
summar
current
effort
gener
recombin
chimer
vaccin
hmpv
discuss
potenti
optim
base
correspond
rsv
studi
acut
respiratori
tract
infect
rti
th
lead
global
caus
mortal
among
age
group
rd
lead
mortal
caus
children
younger
year
old
import
number
rti
caus
virus
belong
pneumovirida
famili
name
respiratori
syncyti
viru
rsv
human
metapneumoviru
hmpv
respons
approxim
rti
children
respect
hmpv
singlestrand
negativesens
rna
viru
belong
famili
pneumovirida
genu
metapneumoviru
genu
two
speci
human
avian
metapneumoviru
ampv
hmpv
divid
two
major
genet
subtyp
b
divid
sublineag
lineag
b
share
nucleotid
amino
acid
sequenc
ident
correspondingli
major
antigen
hmpv
f
protein
highli
conserv
high
level
crossneutr
crossprotect
observ
two
lineag
clinic
sign
hmpv
diseas
vari
significantli
differ
genet
lineag
hmpv
ampv
previous
known
turkey
rhinotrach
viru
import
poultri
pathogen
divid
subgroup
b
c
subgroup
c
ampvc
share
amino
acid
ident
n
p
f
protein
hmpv
make
closest
relat
viru
hmpv
hmpv
rel
newlydiscov
pathogen
describ
first
time
research
netherland
late
identif
explain
similar
symptom
caus
hmpv
rsv
well
difficulti
observ
hmpv
growth
vitro
virus
caus
pneumonia
bronchiol
variabl
sever
ill
accord
age
although
hmpv
diseas
gener
less
sever
compar
rsv
incid
infect
caus
hmpv
similar
influenza
parainfluenza
caus
signific
number
hospit
everi
year
infect
either
viru
associ
develop
asthma
exacerb
yet
causal
relationship
establish
although
pneumovirus
infect
age
group
caus
greatest
diseas
sever
young
infant
hmpv
infect
mainli
children
month
age
wherea
rsv
infect
infant
earlier
within
first
month
birth
virtual
everi
child
infect
rsv
age
hmpv
age
incid
reinfect
virus
increas
significantli
age
caus
lot
rti
elderli
anoth
popul
risk
hmpv
infect
compris
immunosuppress
patient
despit
high
frequenc
pneumovir
infect
year
research
field
licens
vaccin
hmpv
rsv
current
avail
among
numer
vaccin
candid
rsv
develop
advanc
clinic
trial
fail
result
insuffici
immunogen
underattenu
antihmpv
vaccin
advanc
clinic
trial
nowa
liveattenu
recombin
rhmpvp
viru
hmpvp
protein
exchang
counterpart
ampvcprov
insuffici
immunogen
overattenu
seroneg
children
thu
leav
advanc
candid
antihmpv
vaccin
lack
effect
vaccin
candid
hmpv
explain
recent
discoveri
viru
also
lack
success
vaccin
close
relat
rsv
could
serv
base
vaccin
design
one
reason
slow
progress
field
clinic
failur
formalininactiv
rsvvaccin
firsv
occur
administr
firsv
led
develop
exagger
immun
respons
wild
type
wt
rsv
infect
enhanc
pulmonari
diseas
epd
two
vaccin
children
die
epd
document
variou
anim
model
indic
human
phenomenon
similar
effect
observ
formalin
heatinactiv
hmpv
vaccin
induc
symptom
epd
rodent
anoth
reason
slow
vaccin
develop
transient
immun
provid
natur
infect
rsv
hmpv
document
rsvseroposit
adult
level
rsvneutral
antibodi
correl
resist
subsequ
rsv
infect
protect
confer
incomplet
shortlast
result
frequent
reinfect
immun
respons
primari
hmpv
infect
describ
weak
aberr
balbc
mice
excess
product
later
stage
infect
correl
airway
hyperrespons
develop
asthma
pneumovirus
also
develop
mani
mechan
evad
immun
respons
rsv
nonstructur
protein
suppress
ifninduc
antivir
respons
infect
cell
remov
protein
result
induct
high
level
ifn
alpha
beta
vitro
hmpv
share
rsv
abil
decreas
ifn
respons
despit
lack
protein
document
hmpvg
protein
abil
inhibit
ifn
type
respons
vitro
vivo
sh
protein
also
modul
host
immun
respons
hmpv
rsv
persist
lung
infect
anim
host
despit
presenc
neutral
antibodi
persist
document
rtpcr
detect
viral
rna
guinea
pig
mous
model
rsv
mice
hmpv
anoth
hurdl
effect
immun
presenc
matern
antibodi
bloodstream
vaccin
infant
impair
immunogen
effect
vaccin
yet
role
matern
antibodi
rsv
infect
fulli
understood
main
object
pneumoviru
vaccin
develop
avoid
epd
obtain
suffici
immunogen
without
caus
diseas
viral
protein
antigen
use
subunit
vaccin
exampl
rearrang
order
gene
term
express
gradient
observ
paramyxovirus
gene
order
also
chang
invas
way
move
virul
gene
highexpress
posit
lowexpress
locu
altern
replic
effici
decreas
delet
silenc
nonessenti
viral
protein
play
accessori
function
life
cycl
viru
also
possibl
swap
gene
strain
differ
host
prefer
thu
introduc
new
host
rang
restrict
hmpv
viru
p
gene
exchang
ampvc
counterpart
rhmpvp
attenu
wt
hmpv
yet
protect
hmpv
infect
african
green
monkey
agm
review
focu
discuss
detail
develop
live
recombin
vaccin
hmpv
ultim
goal
hmpv
vaccin
prevent
lower
rti
popul
risk
similarli
rsv
target
popul
hmpv
vaccin
young
children
elderli
peopl
pregnant
women
earli
vaccin
infant
young
children
potenti
prevent
hmpvinfect
transmiss
viru
replicationcompet
vaccin
name
liveattenu
hmpv
recombin
virus
good
choic
popul
anoth
vaccin
strategi
primeboost
regimen
consist
vaccin
genebasedl
vaccin
first
proteinparticlebas
vaccin
immun
pregnant
women
provid
passiv
antibodi
transfer
children
also
prevent
mothertochild
transmiss
hmpv
live
vaccin
consid
riski
use
popul
therefor
subunit
vaccin
vlp
standard
adjuv
consid
effect
vaccin
adult
popul
live
vaccin
hamper
presenc
antihmpv
antibodi
bloodstream
respiratori
tract
rt
vaccin
elderli
peopl
experienc
multipl
hmpv
infect
subunit
vlp
potent
adjuv
recommend
one
strategi
aim
circumv
problem
incomplet
immun
provid
natur
hmpv
infect
express
protect
antigen
backbon
immunogen
viru
increas
immunogen
also
provid
improv
antigen
express
vector
demonstr
recombin
bovinehuman
express
either
rsvf
g
protein
human
parainfluenza
type
viru
express
hmpv
antigen
hmpv
difficult
grow
cell
cultur
vector
antigen
backbon
betterrepl
viru
facilit
vaccin
develop
manufactur
instanc
express
rsvf
reach
higher
viral
titer
vivo
compar
wt
rsv
replic
effici
rt
agm
wt
rsv
hmpv
express
foreign
antigen
backbon
anoth
viru
also
mitig
problem
preexist
immun
often
diminish
effect
vaccin
use
vector
anoth
host
rang
facilit
immun
seroposit
individu
risk
caus
diseas
describ
newcastl
diseas
viru
ndv
express
rsvf
major
live
vaccin
rsv
hmpv
date
attenu
codon
chang
genom
therefor
use
stabli
attenu
backbon
render
attenu
reliabl
decreas
risk
revers
attenu
phenotyp
insert
addit
gene
influenc
viru
replic
capac
thu
limit
abil
spread
caus
diseas
also
creat
risk
overattenu
subtl
balanc
attenu
immunogen
remain
major
challeng
vaccin
develop
gener
vectorbas
chimer
vaccin
retain
advantag
live
attenu
vaccin
readili
gener
revers
genet
backbon
use
far
vector
pneumovir
antigen
belong
paramyxovirida
famili
virus
close
relat
phylogenet
structur
pneumovirus
close
relationship
increas
chanc
effici
express
integr
pneumovir
protein
background
paramyxovir
vector
among
paramyxovirus
wide
use
vaccin
backbon
bovin
parainfluenza
viru
type
recombin
deriv
parainfluenza
viru
type
newcastl
diseas
viru
ndv
sendai
viru
sev
reason
explain
frequent
use
paramyxovirus
vaccin
backbon
numer
first
genom
wellcharacter
complet
genom
sequenc
known
member
famili
easili
access
second
genom
simpl
organ
modular
way
tandem
align
gene
transcrib
separ
mrna
product
facilit
genet
manipul
third
paramyxovirus
abl
replic
effici
cell
line
certifi
vaccin
manufactur
vero
cell
facilit
vaccin
develop
fourth
replic
entir
cytoplasm
replic
cycl
involv
integr
host
cell
genom
use
potenti
safe
also
recombin
event
mononegavirus
observ
natur
remain
extrem
rare
vitro
even
optim
condit
indic
low
probabl
gene
exchang
engin
vaccin
virus
pathogen
present
environ
fifth
small
probabl
recombin
also
contribut
stabil
genet
insert
provid
stabl
foreign
gene
express
system
paramyxovirus
abl
stabli
express
sever
exogen
simultan
level
express
manipul
chang
posit
gene
insert
sixth
paramyxovirus
infect
host
via
rt
repres
easi
safe
rout
administr
vaccin
well
induct
local
system
immun
respons
last
least
mani
anim
paramyxovirus
natur
attenu
human
due
host
rang
restrict
mutat
render
virus
harmless
peopl
identifi
character
thu
make
attenu
differ
paramyxovirus
possibl
neg
strand
virus
readili
recov
cell
cultur
mean
revers
genet
techniqu
make
possibl
engin
fulli
function
viru
start
genet
sequenc
genet
materi
form
cdna
easili
modifi
accord
vaccin
design
techniqu
base
transfect
permiss
cell
plasmid
code
viral
genom
satellit
plasmid
code
protein
necessari
format
ribonucleoprotein
complex
rnp
initi
transcript
viral
gene
figur
protein
indispens
form
rnp
paramyxovirus
pneumovirus
n
p
l
protein
yet
addit
protein
facilit
recoveri
hmpv
cdna
elabor
polyval
vaccin
accomplish
either
clone
addit
gene
plasmid
code
viral
genom
replac
protect
antigen
vector
one
anoth
pathogen
wellcharacter
complet
genom
sequenc
known
member
famili
easili
access
second
genom
simpl
organ
modular
way
tandem
align
gene
transcrib
separ
mrna
product
facilit
genet
manipul
third
paramyxovirus
abl
replic
effici
cell
line
certifi
vaccin
manufactur
vero
cell
facilit
vaccin
develop
fourth
replic
entir
cytoplasm
replic
cycl
involv
integr
host
cell
genom
use
potenti
safe
also
recombin
event
mononegavirus
observ
natur
remain
extrem
rare
vitro
even
optim
condit
indic
low
probabl
gene
exchang
engin
vaccin
virus
pathogen
present
environ
fifth
small
probabl
recombin
also
contribut
stabil
genet
insert
provid
stabl
foreign
gene
express
system
paramyxovirus
abl
stabli
express
sever
exogen
simultan
level
express
manipul
chang
posit
gene
insert
sixth
paramyxovirus
infect
host
via
rt
repres
easi
safe
rout
administr
vaccin
well
induct
local
system
immun
respons
last
least
mani
anim
paramyxovirus
natur
attenu
human
due
host
rang
restrict
mutat
render
virus
harmless
peopl
identifi
character
thu
make
attenu
differ
paramyxovirus
possibl
neg
strand
virus
readili
recov
cell
cultur
mean
revers
genet
techniqu
make
possibl
engin
fulli
function
viru
start
genet
sequenc
genet
materi
form
cdna
easili
modifi
accord
vaccin
design
techniqu
base
transfect
permiss
cell
plasmid
code
viral
genom
satellit
plasmid
code
protein
necessari
format
ribonucleoprotein
complex
rnp
initi
transcript
viral
gene
figur
protein
indispens
form
rnp
paramyxovirus
pneumovirus
n
p
l
protein
yet
addit
protein
facilit
recoveri
hmpv
cdna
elabor
polyval
vaccin
accomplish
either
clone
addit
gene
plasmid
code
viral
genom
replac
protect
antigen
vector
one
anoth
pathogen
genom
contain
trailer
sequenc
tr
variabl
length
rang
nucleotid
genom
rna
paramyxovirus
pneumovirus
exist
unbound
rnaparticl
alway
assembl
numer
copi
n
protein
form
helicoid
nucleocapsid
paramyxovirus
n
protein
molecul
associ
precis
six
nucleotid
featur
believ
underlay
rule
six
ie
length
genom
paramyxovirus
multipl
six
effect
viral
replic
stringent
adhes
rule
observ
sev
virus
like
ndv
strongli
increas
efficaci
replic
fact
give
replic
advantag
rsv
might
explain
distinct
differ
nucleocapsid
structur
two
famili
transcript
viral
genom
initi
express
gradient
observ
complex
vrnap
sporad
fail
resum
synthesi
anoth
distinct
mrna
gene
junction
result
gradual
loss
transcriptionefficaci
along
genom
main
principl
taken
consider
engin
genom
recombin
paramyxovirus
preferenti
adher
rule
six
coher
transcript
control
signal
gsge
use
drive
express
foreign
antigen
exogen
posit
transcript
gradient
document
numer
studi
gs
ge
signal
vector
viru
effici
direct
express
exogen
protein
although
gs
ge
signal
often
highli
conserv
along
viral
genom
might
variat
sequenc
transcript
efficaci
flank
sequenc
gfp
insert
th
genom
posit
gsge
specif
either
nd
th
gene
junction
result
larg
differ
genom
contain
trailer
sequenc
tr
variabl
length
rang
nucleotid
genom
rna
paramyxovirus
pneumovirus
exist
unbound
rnaparticl
alway
assembl
numer
copi
n
protein
form
helicoid
nucleocapsid
paramyxovirus
n
protein
molecul
associ
precis
six
nucleotid
featur
believ
underlay
rule
six
ie
length
genom
paramyxovirus
multipl
six
effect
viral
replic
stringent
adhes
rule
observ
sev
virus
like
ndv
strongli
increas
efficaci
replic
fact
give
replic
advantag
rsv
might
explain
distinct
differ
nucleocapsid
structur
two
famili
transcript
viral
genom
initi
express
gradient
observ
complex
vrnap
sporad
fail
resum
synthesi
anoth
distinct
mrna
gene
junction
result
gradual
loss
transcriptionefficaci
along
genom
main
principl
taken
consider
engin
genom
recombin
paramyxovirus
preferenti
adher
rule
six
coher
transcript
control
signal
gsge
use
drive
express
foreign
antigen
exogen
posit
transcript
gradient
document
numer
studi
gs
ge
signal
vector
viru
effici
direct
express
exogen
protein
although
gs
ge
signal
often
highli
conserv
along
viral
genom
might
variat
sequenc
transcript
efficaci
flank
sequenc
gfp
insert
th
genom
posit
gsge
specif
either
nd
th
gene
junction
result
larg
differ
gfp
express
level
figur
gsge
characterist
st
junction
provid
better
express
level
one
origin
th
therefor
import
flank
exogen
potent
transcript
regul
accord
transcript
gradient
exogen
place
posit
express
better
insert
yet
tendenc
describ
linear
deviat
observ
adher
gradient
might
also
influenc
type
attenu
vector
viru
demonstr
bear
rsvf
protein
posit
exogen
viral
genom
describ
figur
nomenclatur
use
label
chimer
virus
review
explain
figur
gfp
express
level
figur
gsge
characterist
st
junction
provid
better
express
level
one
origin
th
therefor
import
flank
exogen
potent
transcript
regul
accord
transcript
gradient
exogen
place
posit
express
better
insert
yet
tendenc
describ
linear
deviat
observ
adher
gradient
might
also
influenc
type
attenu
vector
viru
demonstr
bear
rsvf
protein
posit
exogen
viral
genom
describ
figur
nomenclatur
use
label
chimer
virus
review
explain
figur
one
hand
insert
provid
best
level
express
hand
influenc
level
transcript
downstream
gene
lead
decreas
viral
replic
rsvf
insert
st
posit
genom
reduc
express
downstream
gene
nd
genom
posit
provid
good
express
also
influenc
n
p
protein
ratio
play
decis
role
replic
capac
paramyxovirus
caus
addit
attenu
effect
insert
either
st
nd
genom
posit
privileg
vector
nd
posit
usual
provid
better
viru
recoveri
higher
viral
replic
better
exogen
express
vector
name
ndv
avian
paramyxoviru
serotyp
rd
posit
advantag
wherea
insert
nd
one
result
delay
viral
replic
largest
reduct
viru
recoveri
th
th
posit
frequent
use
influenc
express
vector
surfac
protein
f
hn
except
studi
sev
bear
either
rsvf
hmpvf
th
posit
natur
insert
also
influenc
vector
biolog
viru
show
reduc
replic
vitro
compar
wherea
rsvg
insert
influenc
viral
replic
decreas
viral
growth
might
due
excess
syncytia
format
increas
cytopatholog
result
express
second
fusion
protein
anoth
reason
might
size
inserta
bigger
f
protein
might
influenc
replic
significantli
smaller
g
protein
size
exogen
gfp
express
level
figur
gsge
characterist
st
junction
provid
better
express
level
one
origin
th
therefor
import
flank
exogen
potent
transcript
regul
accord
transcript
gradient
exogen
place
posit
express
better
insert
yet
tendenc
describ
linear
deviat
observ
adher
gradient
might
also
influenc
type
attenu
vector
viru
demonstr
bear
rsvf
protein
posit
exogen
viral
genom
describ
figur
nomenclatur
use
label
chimer
virus
review
explain
figur
one
hand
insert
provid
best
level
express
hand
influenc
level
transcript
downstream
gene
lead
decreas
viral
replic
rsvf
insert
st
posit
genom
reduc
express
downstream
gene
nd
genom
posit
provid
good
express
also
influenc
n
p
protein
ratio
play
decis
role
replic
capac
paramyxovirus
caus
addit
attenu
effect
insert
either
st
nd
genom
posit
privileg
vector
nd
posit
usual
provid
better
viru
recoveri
higher
viral
replic
better
exogen
express
vector
name
ndv
avian
paramyxoviru
serotyp
rd
posit
advantag
wherea
insert
nd
one
result
delay
viral
replic
largest
reduct
viru
recoveri
th
th
posit
frequent
use
influenc
express
vector
surfac
protein
f
hn
except
studi
sev
bear
either
rsvf
hmpvf
th
posit
natur
insert
also
influenc
vector
biolog
viru
show
reduc
replic
vitro
compar
wherea
rsvg
insert
influenc
viral
replic
decreas
viral
growth
might
due
excess
syncytia
format
increas
cytopatholog
result
express
second
fusion
protein
anoth
reason
might
size
inserta
bigger
f
protein
might
influenc
replic
significantli
smaller
g
protein
size
exogen
one
hand
insert
provid
best
level
express
hand
influenc
level
transcript
downstream
gene
lead
decreas
viral
replic
rsvf
insert
st
posit
genom
reduc
express
downstream
gene
nd
genom
posit
provid
good
express
also
influenc
n
p
protein
ratio
play
decis
role
replic
capac
paramyxovirus
caus
addit
attenu
effect
insert
either
st
nd
genom
posit
privileg
vector
nd
posit
usual
provid
better
viru
recoveri
higher
viral
replic
better
exogen
express
vector
name
ndv
avian
paramyxoviru
serotyp
rd
posit
advantag
wherea
insert
nd
one
result
delay
viral
replic
largest
reduct
viru
recoveri
th
th
posit
frequent
use
influenc
express
vector
surfac
protein
f
hn
except
studi
sev
bear
either
rsvf
hmpvf
th
posit
natur
insert
also
influenc
vector
biolog
viru
show
reduc
replic
vitro
compar
wherea
rsvg
insert
influenc
viral
replic
decreas
viral
growth
might
due
excess
syncytia
format
increas
cytopatholog
result
express
second
fusion
protein
anoth
reason
might
size
inserta
bigger
f
protein
might
influenc
replic
significantli
smaller
g
protein
size
exogen
significantli
chang
replic
capac
viru
shown
vector
bear
insert
differ
size
level
integr
foreign
protein
vector
particl
also
price
pay
exchang
effici
express
exogen
describ
chapter
review
improv
exogen
integr
vector
backbon
obtain
substitut
transmembran
domain
tm
cytoplasm
tail
ct
insert
equival
vector
viru
demonstr
vector
bear
rsvf
protein
either
wt
chimer
tmct
form
packag
rsvf
tmct
strongli
improv
chimer
viru
overattenu
protect
hamster
replac
f
hn
gene
counterpart
result
elabor
recombin
viru
broadli
use
express
foreign
antigen
viru
immunogen
human
retain
attenu
profil
safeti
immunogen
document
adult
children
reach
higher
titer
vivo
rsv
make
good
platform
studi
antipneumovir
vaccin
genom
approxim
kb
length
includ
six
structur
gene
adher
rule
six
sever
virus
recov
genom
cdna
whose
length
fulfil
condit
found
accommod
nucleotid
insert
correct
genom
length
broadli
use
express
rsv
hmpv
antigen
exampl
vaccin
test
preclin
trial
shown
tabl
mani
differ
posit
test
rsvf
insert
gradual
decreas
exogen
express
observ
st
th
one
although
time
attenu
rd
th
posit
nd
one
provid
attract
attenuationexogen
express
ratio
viru
bear
rsvf
nd
posit
develop
medimmun
test
phase
clinic
trial
proven
insuffici
immunogen
accommod
insert
rsvf
g
protein
st
posit
littl
decreas
replic
vitro
doubl
insert
place
th
posit
result
ts
phenotyp
restrict
replic
vivo
yet
viru
immunogen
protect
hamster
insert
hmpvf
gene
either
st
nd
posit
genom
result
effici
exogen
express
integr
membran
protein
hmpvf
chimera
difficult
recov
replic
less
effici
observ
rsvf
insert
virus
immunogen
protect
hamster
hmpvf
viru
subsequ
evalu
vaccin
african
green
monkey
agm
viru
replic
better
wt
hmpv
protect
wt
hmpv
challeng
induc
effect
antihmpvspecif
tcell
respons
slightli
lower
compar
wt
hmpv
level
antibodi
induc
chimer
viru
correl
provid
protect
lower
respiratori
tract
lrt
infect
primat
infant
hmpv
rsv
depend
antigen
insert
b
mean
reciproc
log
fold
increas
plaqu
reduct
neutral
assay
standard
error
differ
se
c
log
fold
increas
serum
immunoglobulin
g
igg
titer
determin
elisa
simultan
immun
intranas
intratrach
e
daili
mean
peak
titer
dpc
f
daili
mean
peak
titer
collect
dpc
g
daili
mean
peak
titer
collect
dpc
h
anim
immun
tcid
mixtur
two
virus
sol
solubl
protein
lack
tmct
domain
rt
respiratori
tract
urt
lrt
upper
lower
rt
respect
agm
african
green
monkey
nd
determin
dpi
day
post
last
immun
dpc
day
post
challeng
human
parainfluenza
type
major
caus
croup
respons
approxim
hpiv
infect
children
age
import
pediatr
pathogen
protect
vaccin
avail
use
viru
backbon
bival
vaccin
highli
warrant
share
genom
organ
hpiv
virus
recombin
test
vaccin
preclin
studi
agm
rhpivc
hn
l
attenu
mutat
pc
hn
l
gene
test
vaccin
children
shown
welltoler
overattenu
consid
addit
attenu
effect
exogen
insert
subsequ
studi
concentr
bear
singl
attenu
mutationeith
c
l
exampl
vaccin
shown
tabl
mackow
et
al
test
vector
express
rsvf
st
nd
rd
genom
posit
show
backbon
overattenu
upon
rsvf
insert
backbon
suitabl
vector
subsequ
test
express
either
nativ
rsvf
chimer
rsvf
tmct
protein
st
nd
posit
wild
type
test
vector
express
f
g
sh
surfac
protein
hmpv
examin
rel
contribut
induc
hmpvspecif
antibodi
contrari
g
sh
insert
f
insert
impair
viru
growth
express
vector
hn
gene
vaccin
provid
signific
protect
wt
hmpv
challeng
even
two
dose
less
protect
singl
immun
wt
hmpv
studi
show
hmpvf
major
viral
antigen
immunogen
hmpvg
sh
backbon
also
use
express
f
protein
hmpva
evalu
abil
induc
crossprotect
hmpvb
studi
show
f
protein
hmpva
induc
crossprotect
heterolog
hmpv
strain
backbon
suitabl
vector
hmpv
antigen
sendai
viru
sev
murin
parainfluenza
type
viru
natur
host
rang
restrict
provid
safeti
human
risk
revers
attenu
phenotyp
capabl
induc
durabl
strong
immun
respons
sev
close
relat
develop
heterolog
vaccin
increas
protect
infect
anim
model
human
length
sev
genom
approxim
kb
viru
strictli
adher
rule
six
effici
replic
sev
shown
accommod
stabli
express
insert
kb
size
replic
rate
invers
correl
total
genom
length
broadli
use
backbon
express
rsvf
g
protein
th
genom
posit
test
vaccin
alon
formul
multipl
recombin
sev
express
antigen
differ
hpiv
type
th
genom
posit
also
use
express
hmpvf
viru
recov
revers
genet
although
delet
exogen
sequenc
result
express
truncat
hmpvf
protein
amino
acid
length
retain
part
compris
signal
peptid
fusion
peptid
heptad
repeat
fragment
part
lack
heptad
repeat
b
tm
ct
domain
although
truncat
protein
immunogen
confer
protect
wt
immun
hamster
studi
show
vector
hmpv
antigen
sev
promis
strategi
solubl
form
hmpvf
protein
remain
immunogen
exampl
chimer
sev
shown
tabl
tabl
exampl
sevbas
vaccin
either
rsv
hmpv
immunogen
protect
anim
model
hmpv
rsv
depend
antigen
insert
b
mean
plaqu
reduct
sera
dilut
c
mean
reciproc
log
fold
increas
serum
dilut
viru
infect
inhibit
ic
e
mean
viru
titer
dpc
lrt
lower
respiratori
tract
sol
solubl
version
antigen
tr
truncat
protein
agm
african
green
monkey
eid
effect
infecti
dose
egg
dpi
day
post
last
immun
dpc
day
post
challeng
dl
detect
limit
detect
newcastl
diseas
viru
avian
paramyxoviru
serotyp
viru
import
poultri
pathogen
recent
drew
lot
attent
potenti
use
oncolyt
agent
vaccin
vector
although
recogn
avian
pathogen
experiment
proven
infect
sever
mammal
speci
includ
mice
hamster
guinea
pig
rabbit
ferret
calv
pig
nonhuman
primat
natur
ndv
infect
rare
human
case
infect
document
bird
handler
expos
viru
humantohuman
transmiss
ever
observ
variou
ndv
strain
classifi
low
virul
lentogen
mildli
virul
mesogen
highli
virul
velogen
concern
high
contagi
ndv
potenti
detriment
impact
poultri
industri
lentogen
strain
ndv
classifi
biosafeti
level
pathogen
mesogen
velogen
strain
pathogen
lentogen
strain
name
lasota
use
naturallyattenu
vaccin
protect
poultri
although
mesogen
ndv
strain
frequent
use
vaccin
vector
mesogen
strain
beaudett
c
bc
test
vaccin
vector
protein
nonhuman
primat
welltoler
immunogen
compar
lasota
strain
similarli
sev
ndv
safe
human
due
natur
host
rang
restrict
presenc
preexist
immun
highli
immunogen
induc
potent
ifn
type
respons
genom
approxim
kb
length
viru
adher
rule
six
effici
replic
viru
accommod
exogen
kb
length
effect
express
three
addit
protein
exogen
place
gene
junction
two
gene
viru
yet
rd
posit
found
optim
ndv
vector
st
nd
one
least
optim
ndv
use
vector
antigen
rsv
ampv
hiv
influenza
viru
sarscoronaviru
nipah
viru
ebola
viru
exampl
ndv
vector
pneumovir
antigen
report
tabl
although
ndv
yet
use
vector
hmpv
antigen
found
effici
backbon
surfac
protein
ampvc
lasota
ndv
strain
use
vector
g
protein
ampvc
test
bival
vaccin
ndv
ampvc
turkey
ndvampv
c
g
viru
confer
partial
protect
vaccin
bird
indic
ampvcg
protein
alon
suffici
induc
protect
immun
immunogen
construct
strongli
improv
ampvcf
g
protein
express
togeth
th
genom
posit
ndv
genom
similarli
hmpv
f
protein
ampvc
indispens
induc
potent
immun
respons
vaccin
host
tabl
exampl
ndvbase
vaccin
either
rsv
ampv
immunogen
protect
anim
model
c
e
ampv
c
g
f
c
e
ampvc
rsv
depend
antigen
insert
b
determin
elisa
c
immun
bird
seroconvert
dpi
singl
immun
dpi
primeboost
immun
prime
boost
immun
interv
e
bird
detect
challeng
viru
rna
shed
result
dpi
f
bird
detect
challeng
viru
rna
shed
result
dpc
id
infect
dose
lrt
lower
respiratori
tract
dpi
day
post
immun
dpc
day
post
challeng
vesicular
stomat
viru
pathogen
hors
livestock
belong
rhabdovirida
famili
rhabdovirida
paramyxovirida
belong
order
negativestrand
virus
mononegaviral
genom
vsv
singlestrand
nonseg
rna
neg
polar
approxim
kb
length
due
simplic
genom
use
model
studi
transcript
replic
nonseg
negativestrand
virus
nnsv
figur
pathogen
x
peer
review
virus
mononegaviral
genom
vsv
singlestrand
nonseg
rna
neg
polar
approxim
kb
length
due
simplic
genom
use
model
studi
transcript
replic
nonseg
negativestrand
virus
nnsv
figur
vsv
share
advantag
viral
vector
paramyxovirus
although
superior
growth
vitro
provid
good
level
protein
express
chloramphenicol
acetyltransferas
protein
cat
express
th
posit
vsv
genom
constitut
protein
produc
rvsvinfect
cell
express
vsv
gene
follow
polar
gradient
observ
paramyxovirus
insert
posit
influenc
n
p
protein
ratio
detriment
viru
replic
n
p
ratio
shown
optim
viral
replic
wherea
ratio
valu
associ
decreas
replic
capac
viru
vsv
vector
two
potenti
drawback
name
neurotox
mediat
g
protein
induct
potent
vsvneutral
antibodi
respons
specif
g
protein
even
upon
singl
immun
make
boost
heterolog
vaccin
imposs
limit
futur
use
vsvbase
vaccin
vaccin
patient
neurotrop
result
signific
viral
replic
brain
mortal
mice
infect
vsv
rais
seriou
concern
use
viru
vaccin
vector
although
vsv
human
pathogen
human
infect
occur
result
contact
infect
anim
one
case
enceph
caus
vsv
infect
report
boy
panama
signific
morbid
vsvinfect
cattl
vsv
includ
list
potenti
harm
agent
unit
state
depart
agricultur
circumv
problem
gmediat
vsv
neurotox
attenu
vsv
g
protein
exchang
gp
protein
lymphocyt
choriomening
viru
lcmv
call
rvsvgp
design
chimer
viru
use
express
rsvf
protein
th
genom
posit
three
variant
nativ
codonoptim
codonoptim
tmct
domain
exchang
effici
express
nativ
rsvf
rsvg
protein
th
th
genom
posit
respect
also
document
rvsv
virus
test
vivo
rsvf
construct
also
test
context
vsv
backbon
attenu
result
g
protein
delet
studi
show
backbon
attenu
less
immunogen
rvsv
combin
rsvg
antigen
effici
immun
nonpropag
recombin
vsv
bear
delet
membraneproxim
domain
g
protein
vsvg
stem
use
vector
rsvf
g
protein
test
vivo
intranas
intramuscular
vaccin
vsv
also
use
express
hmpvf
protein
studi
aim
design
enzymelink
immunosorb
assay
elisa
specif
hmpv
studi
show
possibl
effici
express
hmpvf
protein
nd
genom
posit
vsv
vector
exampl
vsvbase
chimer
vaccin
describ
tabl
vsv
share
advantag
viral
vector
paramyxovirus
although
superior
growth
vitro
provid
good
level
protein
express
chloramphenicol
acetyltransferas
protein
cat
express
th
posit
vsv
genom
constitut
protein
produc
rvsvinfect
cell
express
vsv
gene
follow
polar
gradient
observ
paramyxovirus
insert
posit
influenc
n
p
protein
ratio
detriment
viru
replic
n
p
ratio
shown
optim
viral
replic
wherea
ratio
valu
associ
decreas
replic
capac
viru
vsv
vector
two
potenti
drawback
name
neurotox
mediat
g
protein
induct
potent
vsvneutral
antibodi
respons
specif
g
protein
even
upon
singl
immun
make
boost
heterolog
vaccin
imposs
limit
futur
use
vsvbase
vaccin
vaccin
patient
neurotrop
result
signific
viral
replic
brain
mortal
mice
infect
vsv
rais
seriou
concern
use
viru
vaccin
vector
although
vsv
human
pathogen
human
infect
occur
result
contact
infect
anim
one
case
enceph
caus
vsv
infect
report
boy
panama
signific
morbid
vsvinfect
cattl
vsv
includ
list
potenti
harm
agent
unit
state
depart
agricultur
circumv
problem
gmediat
vsv
neurotox
attenu
vsv
g
protein
exchang
gp
protein
lymphocyt
choriomening
viru
lcmv
call
rvsvgp
design
chimer
viru
use
express
rsvf
protein
th
genom
posit
three
variant
nativ
codonoptim
codonoptim
tmct
domain
exchang
effici
express
nativ
rsvf
rsvg
protein
th
th
genom
posit
respect
also
document
rvsv
virus
test
vivo
rsvf
construct
also
test
context
vsv
backbon
attenu
result
g
protein
delet
studi
show
backbon
attenu
less
immunogen
rvsv
combin
rsvg
antigen
effici
immun
nonpropag
recombin
vsv
bear
delet
membraneproxim
domain
g
protein
vsvg
stem
use
vector
rsvf
g
protein
test
vivo
intranas
intramuscular
vaccin
vsv
also
use
express
hmpvf
protein
studi
aim
design
enzymelink
immunosorb
assay
elisa
specif
hmpv
studi
show
possibl
effici
express
hmpvf
protein
nd
genom
posit
vsv
vector
exampl
vsvbase
chimer
vaccin
describ
tabl
chimer
vaccin
hmpv
advanc
clinic
trial
far
recombin
hmpv
viru
render
lessinfecti
result
replac
p
orf
counterpart
closelyrel
ampvc
strategi
attenu
base
restrict
replic
vivo
base
host
incompat
viral
compon
first
studi
hmpv
chimera
either
n
rhmpvn
p
rhmpvp
gene
exchang
ampvc
counterpart
test
vaccin
hamster
agm
tabl
n
p
gene
ampvc
share
nucleotid
sequenc
ident
hmpv
counterpart
suggest
good
integr
heterolog
protein
hmpv
particl
rhmpvn
rhmpvp
virus
replic
effici
vitro
compar
parent
hmpv
strain
test
vivo
hamster
replic
chimer
virus
decreas
rhmpvn
slightli
attenu
rhmpvp
chimera
equal
immunogen
protect
vaccin
anim
wt
hmpv
infect
test
agm
rhmpvp
attenu
rhmpvn
almost
equal
immunogen
chimera
confer
protect
wt
hmpv
studi
identifi
attenu
hmpvp
chimera
promis
vaccin
candid
develop
rhmpvp
viru
recent
test
vaccin
phase
clinic
trial
sequenti
adult
hmpvseroposit
hmpvseroneg
children
trial
found
rhmpvp
viru
appropri
restrict
adult
seroposit
children
yet
insuffici
infecti
immunogen
hmpvseroneg
children
thu
leav
candid
antihmpv
vaccin
clinic
trial
describ
mani
studi
perform
viral
vector
mainli
paramyxovirus
express
pneumovir
protein
although
major
studi
focus
develop
antirsv
vaccin
result
indic
potenti
success
vaccin
candid
hmpv
efficaci
chimer
vaccin
hmpv
potenti
improv
mani
way
immunogen
hmpvf
protein
could
increas
codon
optim
human
express
modif
base
degeneraci
genet
code
make
possibl
optim
sequenc
order
improv
express
specif
express
system
exampl
human
cell
codon
optim
along
amino
acid
substitut
render
rsvf
amino
acid
sequenc
ident
earli
passag
origin
isol
heksubstitut
improv
immunogen
rsvf
protein
express
protect
wt
rsv
infect
codon
optim
alon
confer
increas
rsvf
express
heksubstitut
alon
confer
increas
although
exogen
protein
usual
wellexpress
surfac
cell
infect
chimer
virus
effici
incorpor
foreign
protein
viral
particl
remain
challeng
achiev
tmct
domain
swap
insert
vector
demonstr
viru
swap
either
ct
domain
tmct
domain
increas
packag
effici
reach
level
rsvf
packag
wt
rsv
virion
rsvf
tmct
insert
influenc
incorpor
vector
hn
protein
decreas
packag
f
protein
tmct
modif
influenc
viral
replic
vitro
result
fold
increas
attenu
hamster
rhesu
macaqu
respect
similar
packag
improv
restrict
hamster
observ
bear
rsvf
tmct
st
nd
gene
posit
interestingli
neither
ct
tmct
domain
exchang
improv
packag
effici
rsvf
vsvgp
particl
yet
tmct
modif
necessari
effici
express
surfac
protein
virus
exampl
prove
exchang
tmct
domain
could
attract
strategi
increas
incorpor
hmpv
antigen
vector
particl
yet
modif
caus
addit
attenu
effect
chimer
viru
combin
vector
antigen
requir
individu
design
demonstr
immun
express
rsvf
g
effici
simultan
immun
two
singleinsert
chimera
bear
either
rsvf
g
suppos
effect
due
interact
two
surfac
glycoprotein
close
associ
one
anoth
express
simultan
within
infect
cell
consid
structur
similar
rsv
hmpv
might
presum
simultan
express
hmpvf
g
protein
could
benefici
effect
efficaci
vaccin
also
demonstr
ampvc
howev
studi
perform
viruslik
particl
vlp
express
hmpvf
alon
along
g
protein
show
coincorpor
hmpvg
protein
vlp
improv
immunogen
confer
f
protein
therefor
like
coexpress
hmpvf
g
could
improv
vaccin
immunogen
improv
strategi
consid
anoth
possibl
strategi
improv
design
antihmpv
vaccin
could
express
one
copi
hmpv
antigen
hmpv
viru
express
two
addit
copi
f
gene
one
addit
copi
g
gene
st
genom
posit
describ
express
f
g
protein
mrna
recombin
hmpv
increas
respect
compar
wt
hmpv
vitro
replic
recombin
viru
approxim
reduc
compar
wt
hmpv
rel
small
reduct
consid
fact
genom
length
viru
increas
studi
show
ad
addit
copi
orf
hmpvf
orand
g
could
potenti
increas
express
antigen
also
backbon
vector
hmpv
rsv
import
pediatr
pathogen
despit
mani
year
research
vaccin
either
hmpv
rsv
current
avail
underlin
need
novel
solut
vaccin
design
optim
exist
strategi
gener
recombin
chimer
vaccin
protect
one
pathogen
advantag
practic
solut
elabor
promis
vaccin
candid
mani
studi
perform
vaccin
contain
antigen
rsv
express
heterolog
viru
mainli
f
protein
bival
vaccin
advanc
clinic
trial
although
possibl
gener
chimer
vaccin
hmpv
lessexplor
rsv
numer
similar
two
virus
serv
guid
design
antihmpv
vaccin
antigen
hmpv
rsv
success
express
variou
viral
vector
belong
paramyxovirida
famili
notwithstand
paramyxovirus
readili
express
exogen
protein
ad
gene
genom
mani
differ
factor
condit
viabil
chimer
viru
efficaci
exogen
express
immunogen
vaccin
candid
choic
vector
viru
need
taken
consider
variou
aspect
name
posit
exogen
vector
genom
size
type
insert
possibl
integr
foreign
protein
vector
particl
thoroughli
consid
numer
studi
engin
chimer
virus
indic
combin
exogenevector
must
care
design
individu
verifi
recombin
vaccin
candid
either
hmpv
rsv
design
date
indic
use
anoth
viru
express
hmpv
antigen
vice
versa
make
possibl
overcom
major
hurdl
hmpv
vaccin
develop
obtain
good
balanc
immunogen
attenu
live
recombin
vaccin
fund
research
fund
cihr
author
declar
conflict
interest
